학술논문

Systematic Review and Appraisal of the Cross‐Cultural Validity of Functional Status Assessment Measures in Rheumatoid Arthritis
Document Type
article
Source
Arthritis Care & Research. 72(6)
Subject
Health Services and Systems
Health Sciences
Arthritis
Clinical Research
Arthritis
Rheumatoid
Culturally Competent Care
Disability Evaluation
Health Status Indicators
Humans
Reproducibility of Results
Clinical Sciences
Public Health and Health Services
Psychology
Clinical sciences
Allied health and rehabilitation science
Language
Abstract
ObjectiveWe conducted a systematic review and appraisal of the cross-cultural adaptation and cross-cultural validity of the Health Assessment Questionnaire (HAQ) and its derivatives, and of the more recent Patient-Reported Outcomes Measurement Information System (PROMIS) functional status assessment measures (FSAMs) in rheumatoid arthritis.MethodsFour electronic medical databases were searched from inception until April 4, 2018 according to the Consensus-Based Standards for the Selection of Health Measurement Instruments (COSMIN) group search strategy. Included studies were evaluated using the COSMIN tool for cross-cultural validity and were scored as excellent, good, fair, or poor.ResultsOf 58 articles identified by our search strategy and 3 by manual search, 39 were included: 29 described the translation, cultural adaptation, or cross-cultural validity of the HAQ disability index, 8 other HAQ derivatives, and 2 PROMIS measures, representing 22 languages. Of the 39 articles reviewed, 3 examined the cross-cultural validity of translated versions. These studies were rated as follows: 2 as excellent, 3 good, 13 fair, and 21 poor. Two studies examining cross-cultural validity noted differential item functioning (DIF) between Dutch and US populations for the HAQ-II and PROMIS measures, and a third study found DIF between Turkish and UK populations on the HAQ, indicating cultural differences in questionnaire response.ConclusionThis review highlights a paucity of data on the cross-cultural validity of FSAMs and the mostly poor- or fair-quality methods by which they were translated and adapted, which needs to be considered when using these measures for multinational clinical trials and for day-to-day use in clinical practice.